Tirzepatide — Peptide Intelligence Monograph

Short description

The Evidence Behind the Hype.

A physician-reviewed, evidence-based examination of tirzepatide from the Founder’s Institute of Medicine & Education.

This digital monograph separates findings supported by randomized human clinical trials and regulatory review from emerging research, mechanistic extrapolation, off-label claims, and questions that remain unanswered.

Full product description

Tirzepatide has transformed the conversation surrounding metabolic disease and weight management. But what does the evidence actually show?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist supported by an unusually substantial body of human clinical research.

Unlike many compounds discussed in the peptide marketplace, tirzepatide has undergone large randomized controlled trials and regulatory evaluation. Yet its rapid adoption has also generated claims that extend well beyond what has been firmly established.

The Tirzepatide Peptide Intelligence Monograph examines the evidence systematically—distinguishing demonstrated clinical outcomes from mechanistic hypotheses, emerging applications, extrapolation, and promotional claims.

Inside the monograph:

• Tirzepatide pharmacology and dual GIP/GLP-1 receptor activity
• Human randomized clinical-trial evidence
• Glycemic control and metabolic outcomes
• Weight-loss and body-composition evidence
• Cardiometabolic outcomes and risk factors
• Safety, tolerability, and adverse-event evidence
• Regulatory status and approved uses
• Emerging research and proposed applications
• Limitations, uncertainties, and important evidence gaps
• Claim-by-claim FIPES evidence grading
• What we know, what we do not know, and what research is still needed

Physician reviewed. Evidence graded. No protocols. No dosing instructions. No promotional claims.

This publication is intended for education and scientific evidence review. It is not medical advice and does not recommend or instruct the use of tirzepatide.